Alector (ALEC) Net Cash Flow Growth (1y) (2019 - 2026)
Powered by 
Analysis
Alector (ALEC) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 349.49% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -55.11% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 172.72% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 53.21% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 47.11% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -100.75% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,371.48% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -104.22% |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | -350.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -350.76% |
| Mar 31, 2026 | 125.36% |
| Dec 31, 2025 | -178.82% |
| Sep 30, 2025 | 405.53% |
| Jun 30, 2025 | 127.18% |
| Mar 31, 2025 | 347.23% |
| Dec 31, 2024 | 86.00% |
| Sep 30, 2024 | 64.89% |
| Jun 30, 2024 | 60.89% |
| Mar 31, 2024 | -104.86% |
| Dec 31, 2023 | 8.36% |
| Sep 30, 2023 | -347.19% |
| Jun 30, 2023 | 77.36% |
| Mar 31, 2023 | -67.14% |
| Dec 31, 2022 | 84.04% |
| Sep 30, 2022 | -96.94% |
| Jun 30, 2022 | -1,981.11% |
| Mar 31, 2022 | 106.59% |
| Dec 31, 2021 | -435.22% |
| Sep 30, 2021 | 5,295.68% |